Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase NA 2

Status

Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 3

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Aclarubicin × Clear all
NCT04254640 2020-12-17

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Sun Yat-sen University

Phase 2 Unknown
34 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03181815 2019-08-20

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03045627 2017-02-07

Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients

Shandong University

Phase 2 Unknown
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡